公开(公告)号：US20180140585A1

公开(公告)日：2018-05-24

申请号：US15577522

申请日：2016-05-27

申请人： ELECTROPHORETICS LIMITED

发明人： Ian Hugo Pike ,  Malcolm Andrew Ward ,  Claire Louise Russell ,  Vikram Mitra

IPC分类号： A61K31/437 ,  A61K31/13 ,  A61K31/445 ,  A61K31/55 ,  A61K31/57 ,  C07K14/47 ,  C12N9/16 ,  G01N33/68 ,  A61P25/28

CPC分类号： A61K31/437 ,  A61K31/13 ,  A61K31/445 ,  A61K31/55 ,  A61K31/57 ,  A61P25/28 ,  C07K14/4711 ,  C12N9/16 ,  G01N33/6896 ,  G01N2800/2821 ,  G01N2800/50 ,  G01N2800/56 ,  A61K2300/00

摘要： The invention relates to panels of biomarkers including proteins phosphatase 1 regulatory subunit 14A and/or 2′,3′-cyclic-nucleotide 3′-phosphodiesterase and/or phosphorylated tau or fragments thereof and methods using thereof for diagnosing, staging, treating and assessing the response of a treatment for a neurocognitive disorder characterised by tau toxicity, in particular for Alzheimer's disease. The present invention shows that the biomarkers disclosed herein are elevated in the brain of subjects with an advanced stage of a neurocognitive disorder (Braak stage V/VI) and/or are regulated in the CSF of AD subjects in comparison to cognitively affected non-AD controls; and/or regulated in response to two casein kinase 1 delta inhibitors.

公开(公告)号：US20160320395A1

公开(公告)日：2016-11-03

申请号：US15036773

申请日：2014-11-13

申请人： ELECTROPHORETICS LIMITED ,  KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST

发明人： Malcolm Andrew Ward ,  Ian Hugo Pike ,  David James Britton ,  Vikram Mitra ,  Nigel David Heaton ,  Yoh Zen ,  Alberto Quaglia

IPC分类号： G01N33/574 ,  G06F19/18

CPC分类号： G01N33/57438 ,  G01N33/57423 ,  G01N2800/52 ,  G01N2800/60 ,  G16B20/00

摘要： The invention relates to materials and methods for diagnosing liver tumor types, and assessing patient prognosis. Specifically, but not exclusively, the invention concerns the determination of marker protein which enable primary liver tumors to be identified and classified according to the latest WHO classification. Particularly, the invention provides potential markers proteins which allow non-neoplastic and neoplastic hepatocytes and biliary epithelial cells to be distinguished. This allows grading of tumor differentiation to be refined and differential diagnosis of primary liver tumors and pathogenesis of sub-types of cholangiocarcinoma.

摘要翻译： 本发明涉及用于诊断肝肿瘤类型的材料和方法，以及评估患者预后。 具体地，但不排他地，本发明涉及可以根据最新的WHO分类鉴定和分类原发性肝肿瘤的标记蛋白的确定。 特别地，本发明提供潜在的标记蛋白，其允许区分非肿瘤性和肿瘤性肝细胞和胆道上皮细胞。 这允许细分肿瘤分化和原发性肝肿瘤的鉴别诊断和胆管癌的亚型的发病机制。

公开(公告)号：US20160195536A1

公开(公告)日：2016-07-07

申请号：US14912299

申请日：2014-08-13

申请人： Electrophoretics Limited ,  King's College Hospital NHS Foundation Trust

发明人： Yoh Zen ,  Nigel Heaton ,  Alberto Quaglia ,  David Britton ,  Malcolm Ward ,  Ian Pike ,  Vikram Mitra

IPC分类号： G01N33/574 ,  C07K2/00 ,  A61K31/506

CPC分类号： G01N33/57438 ,  A61K31/506 ,  C07K2/00 ,  G01N2440/14 ,  G01N2458/15 ,  G01N2560/00 ,  G01N2570/00

摘要： The present invention concerns materials and methods relating to pancreatic cancer and personalized medicine as applied to pancreatic cancer. Particularly, the invention relates to materials and methods for the determination of significantly modulated protein phosphorylation and/or expression as well as the activity of signalling pathways collectively providing a tumour profile that can guide selection of the most appropriate treatment regime based on the likelihood of tumour recurrence or the identity of activated drug targets in pancreatic cancer.

摘要翻译： 本发明涉及应用于胰腺癌的胰腺癌和个体化医学相关的材料和方法。 特别地，本发明涉及用于确定显着调节的蛋白质磷酸化和/或表达以及信号通路的活性的材料和方法，以及共同提供基于肿瘤可能性的指导选择最合适的治疗方案的肿瘤分布的活动 复发或胰腺癌中活化药物靶标的特征。